핵산 치료제 CDMO 시장 : 유형, 서비스, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Nucleic Acid Therapeutics CDMO Market was valued at USD 9.69 billion in 2023, expected to reach USD 10.58 billion in 2024, and is projected to grow at a CAGR of 9.64%, to USD 18.47 billion by 2030.

As a Market Research Analyst at 360iResearch focusing on the Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) sector, it's essential to understand the scope and nuances of this evolving industry. Nucleic acid therapeutics, including mRNA, siRNA, and antisense oligonucleotides, are reshaping targeted therapies, offering immense promise in treating genetic disorders, cancers, and viral infections. The necessity and application of these therapeutics are underscored by their ability to target genetic conditions directly, providing precision treatment options that traditional therapies may not achieve. End-use is primarily in biotechnology and pharmaceutical companies dedicated to personalized medicine, expanding their R&D pipelines to include these novel modalities. Market growth is driven by technological advancements in genetic sequencing, increasing prevalence of chronic diseases, and a rising trend towards personalized medicine. Moreover, public and private investments are accelerating the development of these groundbreaking therapies. However, challenges persist, such as high production costs, scalability issues, stringent regulatory environments, and complex manufacturing processes that may hinder market expansion. Opportunities lie in innovating cost-effective manufacturing techniques, enhancing delivery mechanisms, and developing partnerships that facilitate technology sharing to overcome current limitations. CDMOs can capitalize on the burgeoning demand by investing in advanced technology platforms that enhance scalability, regulatory compliance, and speed to market, such as integrated digital solutions and automation. Critical areas of innovation include improving delivery systems, such as lipid nanoparticles, and evolving stable formulation technologies that ensure the safe delivery of nucleic acid payloads to targeted cells. Adapting to the market's nature requires an agile approach, expanding portfolios to include comprehensive services spanning from development to commercial manufacturing. By understanding these market dynamics and potential opportunities, businesses can better position themselves to advance nucleic acid therapeutics, addressing unmet medical needs and driving robust growth within this innovative sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of genetic disorders worldwide
  • Increasing funding and investments support nucleic acid research
• Market Restraints
  • High production costs of nucleic acid therapies
• Market Opportunities
  • Rising regulatory approvals for nucleic acid therapies
  • High potential with the expansion of personalized medicine
• Market Challenges
  • Limited scalability of nucleic acid therapies

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid Therapeutics CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid Therapeutics CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid Therapeutics CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid Therapeutics CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid Therapeutics CDMO Market

A detailed market share analysis in the Nucleic Acid Therapeutics CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid Therapeutics CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid Therapeutics CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid Therapeutics CDMO Market

A strategic analysis of the Nucleic Acid Therapeutics CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Rentschler Biopharma SE, Sanofi SA, The Scripps Research Institute, Univercells Group, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid Therapeutics CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across DNA Therapeutics and RNA Therapeutics.
• Based on Service, market is studied across Analytical and Quality Control Services, Manufacturing Services, and Process Development and Optimization.
• Based on Application, market is studied across Genetic Disorders, Infectious Diseases, and Oncology.
• Based on End-user, market is studied across Biotech Companies, Government & Academic Research Institutes, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of genetic disorders worldwide
    • 5.1.1.2. Increasing funding and investments support nucleic acid research
  • 5.1.2. Restraints
    • 5.1.2.1. High production costs of nucleic acid therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising regulatory approvals for nucleic acid therapies
    • 5.1.3.2. High potential with the expansion of personalized medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Limited scalability of nucleic acid therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Ongoing advancements in mRNA therapeutics with rising prevalence of infectious diseases
  • 5.2.2. Application: Rising incidence of cancer push the need for innovative and effective cancer treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Type

• 6.1. Introduction
• 6.2. DNA Therapeutics
• 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service

• 7.1. Introduction
• 7.2. Analytical and Quality Control Services
• 7.3. Manufacturing Services
• 7.4. Process Development and Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Application

• 8.1. Introduction
• 8.2. Genetic Disorders
• 8.3. Infectious Diseases
• 8.4. Oncology

9. Nucleic Acid Therapeutics CDMO Market, by End-user

• 9.1. Introduction
• 9.2. Biotech Companies
• 9.3. Government & Academic Research Institutes
• 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
  • 13.3.2. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AGC Biologics Inc.
• 2. Agilent Technologies, Inc.
• 3. Ajinomoto Bio-Pharma Services
• 4. Almac Group Ltd.
• 5. Biomay AG
• 6. BioSpring GmbH
• 7. Catalent, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. CordenPharma International GmbH
• 10. Creative Biogene
• 11. Danaher Corporation
• 12. Eurofins Scientific SE
• 13. Evonik Industries AG
• 14. GenScript Biotech Corporation
• 15. Lonza Group Ltd.
• 16. Polypeptide Group AG
• 17. Rentschler Biopharma SE
• 18. Sanofi SA
• 19. The Scripps Research Institute
• 20. Univercells Group
• 21. WuXi AppTec Co., Ltd.